Ibrance and Keratitis sicca - a phase IV clinical study of FDA data
Summary:
We study 106,044 people who take Ibrance (palbociclib) or have Keratitis sicca. No report of Keratitis sicca is found in people who take Ibrance.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Ibrance?
Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,433 Ibrance users. Check the latest studies of Ibrance.
What is Keratitis Sicca?
Keratitis sicca (inflammation of the conjunctiva and cornea of the eye with decreased tears) is found to be associated with 396 drugs and 688 conditions by eHealthMe. Check the latest studies of Keratitis sicca.
No report is found.
Do you take Ibrance and have Keratitis sicca?
- Check whether Keratitis sicca is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Ibrance:
- Ibrance (104,433 reports)
Keratitis sicca treatments and more:
- Keratitis sicca (1,611 reports)
How severe was Keratitis sicca and when was it recovered:
Expand to all the drugs that have ingredients of palbociclib:
Browse all side effects of Ibrance:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Keratitis sicca:
Browse all the conditions that are associated with Keratitis sicca:
How the study uses the data?
The study uses data from the FDA. It is based on palbociclib (the active ingredients of Ibrance) and Ibrance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Pravachol cause Photopsia? - 8 seconds ago
- Apixaban and Zosyn drug interactions for men aged 60+ - 18 seconds ago
- Humira and Anaphylaxis for Men aged 40-49 - 19 seconds ago
- Humira and Shock - Anaphylactic for Men aged 40-49 - 20 seconds ago
- Humira and Anaphylactic Shock for Men aged 40-49 - 20 seconds ago
- Atenolol and Hepatomegaly for Women aged 50-59 - 20 seconds ago
- Humira and Anaphylactic Reaction for Men aged 40-49 - 20 seconds ago
- Atenolol and Liver Enlargement for Women aged 50-59 - 21 seconds ago
- Atenolol and Enlarged Liver for Women aged 50-59 - 21 seconds ago
- Atenolol and Hepatosplenomegaly for Women aged 50-59 - 21 seconds ago